All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2019-10-31T12:15:57.000Z

ESH 2019 | What is the impact of EZH2 mutations in AML?

By Brian Huntly
Featured
Brian Huntly
Oct 31, 2019
Share:

Bookmark this article

The AML Global Portal were delighted to speak to Brian Huntly, University of Cambridge, Cambridge, UK, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Brian Huntly: What is the impact of EZH2 mutations in AML?

He outlined the prognostic significance of EZH2 mutations for patients with AML and how they can now be targeted by novel inhibitors.

What is the impact of EZH2 mutations in AML?

More about...
AML-related mutationsESH 2019EZH2

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
26 votes - 57 days left ...

Related articles

Add bookmark

What results are needed prior to therapy initiation in newly diagnosed AML?

Finally, the committee discusses the need for measurable residual disease (MRD) testing prior to initiation of therapy, highlighting recent data and the impact on...

Jul 27, 2022
Add bookmark

What results are needed prior to therapy initiation in newly diagnosed AML?

Finally, the committee discusses the need for measurable residual disease (MRD) testing prior to initiation of therapy,...

Jul 27, 2022
Add bookmark

1st NCRI AML academy meeting

During the 1st NCRI AML academy meeting, Professor Brian Huntly from the University of Cambridge, Cambridge, UK delivered a presentation detailing how genetic studies can facilitate clinical decision making in terms of...

Oct 9, 2019
Add bookmark

1st NCRI AML academy meeting

During the 1st NCRI AML academy meeting, Professor Brian Huntly from the University of Cambridge, Cambridge, UK delivered a presentation detailing how genetic studies can...

Oct 9, 2019

Newsletter

Subscribe to get the best content related to AML delivered to your inbox